Eisai to develop rufinamide for Lennox-Gastaut syndrome in Japan
This article was originally published in Scrip
Executive Summary
Eisai is planning to begin a Phase III clinical programme in Japan for the anticonvulsant agent, rufinamide, for the treatment of Lennox-Gastaut syndrome (LGS).